Could valproic acid be an effective anticancer agent? The evidence so far

被引：46

作者：

Brodie, Seth A. ^{[1
,2
,3
]}

Brandes, Johann C. ^{[1
,2
,3
]}

机构：

[1] Atlanta VAMC, Atlanta, GA 30033 USA

[2] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2014年 / 14卷 / 10期

关键词：

AML; cancer prevention; HDAC; MDS; methylation; valproic acid; ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE INHIBITOR; CONVENTIONAL CARE REGIMENS; TRANS-RETINOIC ACID; MYELODYSPLASTIC SYNDROME; LUNG-CANCER; PHASE-III; TRIAL; RISK; AZACITIDINE;

D O I：

10.1586/14737140.2014.940329

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Valproic acid is an inhibitor of class I histone deacetylases. Epigenetic therapies in cancer have been focus of a keen interest and histone deacetylase inhibitors, in particular, have been approved for certain types of hematologic malignancies. Valproic acid is an attractive candidate for cancer therapy due to its mechanism of action, its low cost and generally good clinical tolerability. In the following editorial, we will review its role as monotherapy for cancer, its place in combination epigenetic therapy, and its role as chemosensitizer, and cancer preventative agent.

引用

页码：1097 / 1100

页数：4

共 22 条

[1]

Class I HDACs Are Mediators of Smoke Carcinogen-Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer [J].

Brodie, Seth A. ;

Li, Ge ;

El-Kommos, Adam ;

Kang, Hyunseok ;

Ramalingam, Suresh S. ;

Behera, Madhusmita ;

Gandhi, Khanjan ;

Kowalski, Jeanne ;

Sica, Gabriel L. ;

Khuri, Fadlo R. ;

Vertino, Paula M. ;

Brandes, Johann C. .

CANCER PREVENTION RESEARCH, 2014, 7 (03) :351-361

[2]

Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer [J].

Chu, B. F. ;

Karpenko, M. J. ;

Liu, Z. ;

Aimiuwu, J. ;

Villalona-Calero, M. A. ;

Chan, K. K. ;

Grever, M. R. ;

Otterson, G. A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) :115-121

[3]

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results [J].

Coronel, Jaime ;

Cetina, Lucely ;

Pacheco, Irlanda ;

Trejo-Becerril, Catalina ;

Gonzalez-Fierro, Aurora ;

de la Cruz-Hernandez, Erick ;

Perez-Cardenas, Enrique ;

Taja-Chayeb, Lucia ;

Arias-Bofill, Daymi ;

Candelaria, Myrna ;

Vidal, Silvia ;

Duenas-Gonzalez, Alfonso .

MEDICAL ONCOLOGY, 2011, 28 :S540-S546

[4]

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial [J].

Daud, Adi I. ;

Dawson, Jana ;

DeConti, Ronald C. ;

Bicaku, Elona ;

Marchion, Douglas ;

Bastien, Sem ;

Hausheer, Frederick A., III ;

Lush, Richard ;

Neuger, Anthony ;

Sullivan, Daniel M. ;

Munster, Pamela N. .

CLINICAL CANCER RESEARCH, 2009, 15 (07) :2479-2487

[5]

DNMT1 Stability Is Regulated by Proteins Coordinating Deubiquitination and Acetylation-Driven Ubiquitination [J].

Du, Zhanwen ;

Song, Jing ;

Wang, Yong ;

Zhao, Yiqing ;

Guda, Kishore ;

Yang, Shuming ;

Kao, Hung-Ying ;

Xu, Yan ;

Willis, Joseph ;

Markowitz, Sanford D. ;

Sedwick, David ;

Ewing, Robert M. ;

Wang, Zhenghe .

SCIENCE SIGNALING, 2010, 3 (146)

[6]

Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies [J].

Falchook, Gerald S. ;

Fu, Siqing ;

Naing, Aung ;

Hong, David S. ;

Hu, Wei ;

Moulder, Stacy ;

Wheler, Jennifer J. ;

Sood, Anil K. ;

Bustinza-Linares, Ernesto ;

Parkhurst, Kristin L. ;

Kurzrock, Razelle .

INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) :1192-1200

[7]

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Gattermann, Norbert ;

Germing, Ulrich ;

Sanz, Guillermo ;

List, Alan F. ;

Gore, Steven ;

Seymour, John F. ;

Dombret, Herve ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :562-569

[8]

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Finelli, Carlo ;

Giagounidis, Aristoteles ;

Schoch, Robert ;

Gattermann, Norbert ;

Sanz, Guillermo ;

List, Alan ;

Gore, Steven D. ;

Seymour, John F. ;

Bennett, John M. ;

Byrd, John ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

LANCET ONCOLOGY, 2009, 10 (03) :223-232

[9]

Histone deacetylase is a target of valproic acid-mediated cellular differentiation [J].

Gurvich, N ;

Tsygankova, OM ;

Meinkoth, JL ;

Kein, PS .

CANCER RESEARCH, 2004, 64 (03) :1079-1086

[10]

Cancer Risk in Long-term Users of Valproate: A Population-Based Case-Control Study [J].

Hallas, Jesper ;

Friis, Soren ;

Bjerrum, Lars ;

Stovring, Henrik ;

Narverud, Sverre Flatabo ;

Heyerdahl, Thomas ;

Gronbaek, Kirsten ;

Andersen, Morten .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (06) :1714-1719

← 1 2 3 →